Results 61 to 70 of about 27,758 (263)
Molecular Oncology, 2015 The MYCN oncogene is amplified in 20% of neuroblastomas, leading to its overexpression at both the mRNA and protein levels. MYCN overexpression is strongly associated with advanced disease stage, rapid tumor progression and a worse prognosis.
Hailong Zhang +4 more
doaj +1 more source
Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma
Nature Communications, 2020 MYCN amplification drives one in six cases of neuroblastoma. The supernumerary gene copies are commonly found on highly rearranged, extrachromosomal circular DNA (ecDNA).
K. Helmsauer +28 more
semanticscholar +1 more source
Molecular Mechanisms of MYCN Dysregulation in Cancers
Frontiers in Oncology, 2021 MYCN, a member of MYC proto-oncogene family, encodes a basic helix-loop-helix transcription factor N-MYC. Abnormal expression of N-MYC is correlated with high-risk cancers and poor prognosis. Initially identified as an amplified oncogene in neuroblastoma
Ruochen Liu +4 more
semanticscholar +1 more source
Angewandte Chemie, EarlyView.Oncogenic MYC is a transcription factor that is difficult to inhibit. However, precise positioning of an acrylamide electrophile in MAX to covalently bond to the unique Cys438 in MYC, enabled shortening and optimizing of MAX‐derived, helix‐constrained peptides with high‐affinity and selectivity.
Aline Dantas de Araujo +7 more
wiley +2 more sources
Drugging the Undruggable: Inhibiting MYCN Signalling
Proceedings, 2019 Neuroblastoma is the most common solid malignancy in early. [...]
Jessica K. Holien +3 more
doaj +1 more source
Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN
Cell Death and Disease, 2023 The transcription factor MYCN is frequently amplified and overexpressed in a variety of cancers including high-risk neuroblastoma (NB) and promotes tumor cell proliferation, survival, and migration.
Xiaoling Zhang +10 more
doaj +1 more source
Frontiers in Oncology, 2021 Purpose MYCN amplification plays a critical role in defining high-risk subgroup of patients with neuroblastoma. We aimed to develop and validate the CT-based machine learning models for predicting MYCN amplification in pediatric abdominal neuroblastoma ...
Xin Chen +8 more
semanticscholar +1 more source
Frontiers in Cell and Developmental Biology, 2021 Although a rare disease, neuroblastoma accounts for the highest proportion of childhood cancer deaths. There is a lack of recurrent somatic mutations in neuroblastoma embryonal tumours, suggesting a possible role for epigenetic alterations in driving ...
Aleksandar Krstic +12 more
doaj +1 more source
Cell Reports MedicineSummary Neuroblastoma with MYCN amplification (MNA) is a high-risk disease that has a poor survival rate. Neuroblastoma displays cellular heterogeneity, including more differentiated (adrenergic) and more primitive (mesenchymal) cellular states. Here, we
A. Abu-Zaid +25 more
semanticscholar +1 more source
Molecules and Cells, 2021 The MYCN oncoprotein drives the development of numerous neuroendocrine and pediatric tumors. Here we show that MYCN interacts with the nuclear RNA exosome, a 3'-5' exoribonuclease complex, and recruits the exosome to its target genes.
D. Papadopoulos +16 more
semanticscholar +1 more source